UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 25

Sortiert nach

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Journal of clinical oncology, 2013-07, Vol.31 (19), p.2388-2395

2013

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

Journal of clinical oncology, 2012-11, Vol.30 (31), p.3810-3818

2012

Link zum Volltext

Verfügbarkeit prüfen

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

Journal of clinical oncology, 2013-07, Vol.31 (19), p.2413-2420

2013

Link zum Volltext

Verfügbarkeit prüfen

Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon‐α: Course and relationship with psychiatric status

Psychiatry and clinical neurosciences, 2008-10, Vol.62 (5), p.597-602

2008

Link zum Volltext

Verfügbarkeit prüfen

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience

Journal of clinical oncology, 2006-05, Vol.24 (13), p.e20-e22

2006

Link zum Volltext

Verfügbarkeit prüfen

Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands

Melanoma research, 2021-06, Vol.31 (3), p.249

2021

Link zum Volltext

Verfügbarkeit prüfen

Pimasertib‐associated ophthalmological adverse events

Acta ophthalmologica (Oxford, England), 2018-11, Vol.96 (7), p.712-718

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma

International journal of cancer, 2005-11, Vol.117 (4), p.596-604

2005

Link zum Volltext

Verfügbarkeit prüfen

Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)

Cancer Immunology, Immunotherapy, 2013-07, Vol.62 (7), p.1223-1233

2013

Link zum Volltext

Verfügbarkeit prüfen

IL-12: a promising adjuvant for cancer vaccination

Cancer Immunology, Immunotherapy, 2003-03, Vol.52 (3), p.133-144

2003

Link zum Volltext

Verfügbarkeit prüfen

Repeated Administrations of Interleukin (IL)-12 Are Associated with Persistently Elevated Plasma Levels of IL-10 and Declining IFN-γ, Tumor Necrosis Factor-α, IL-6, and IL-8 Responses

Clinical cancer research, 2003-01, Vol.9 (1), p.76-83

2003

Link zum Volltext

Verfügbarkeit prüfen

Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-α therapy

Amino acids, 2009-10, Vol.37 (4), p.703-708

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of Subcutaneously Administered Recombinant Human Interleukin 12 in Patients with Advanced Renal Cell Cancer

Clinical cancer research, 1999-12, Vol.5 (12), p.3983-3989

1999

Link zum Volltext

Verfügbarkeit prüfen

Interferon-α Influences Tryptophan Metabolism without Inducing Psychiatric Side Effects

Neuropsychobiology, 2007-01, Vol.55 (3-4), p.225-231

2007

Link zum Volltext

Verfügbarkeit prüfen

Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant

Cancer Immunology, Immunotherapy, 2005-01, Vol.54 (1), p.37-43

2005

Link zum Volltext

Verfügbarkeit prüfen

Pegylated interferon-α2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations

Anti-cancer drugs, 2004-07, Vol.15 (6), p.587-591

2004

Link zum Volltext

Verfügbarkeit prüfen

Interleukin 12 induces activation of fibrinolysis and coagulation in humans

British journal of haematology, 2001-02, Vol.112 (2), p.499-505

2001

Link zum Volltext

Verfügbarkeit prüfen

Side effects of interferon-alpha therapy

Pharmacy world and science, 2005-12, Vol.27 (6), p.423-431

2005

Link zum Volltext

Verfügbarkeit prüfen

Adverse Effect on Bone Marrow Protection of Prechemotherapy Granulocyte Colony-Stimulating Factor Support

JNCI : Journal of the National Cancer Institute, 1996-10, Vol.88 (19), p.1393-1398

1996

Link zum Volltext

Verfügbarkeit prüfen

The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon α and lymphokine-activated killer cells

Cancer Immunology, Immunotherapy, 1999-09, Vol.48 (6), p.331-335

1999

Link zum Volltext

Verfügbarkeit prüfen

Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response

Journal of clinical oncology, 1993-05, Vol.11 (5), p.921-924

1993

Link zum Volltext

Verfügbarkeit prüfen

Neuropsychiatric side effects of interferon-alfa therapy

Pharmacy world and science, 2003-02, Vol.25 (1), p.11

2003

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4603: Targeted treatment of metastatic melanoma through interference with Pin1-FOXM1 signaling

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4603-4603

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 25

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(22)
Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Middle Aged
(16)
Adult
(15)
Aged
(15)
Female
(15)
Oncology
(15)
Male
(14)
Biological And Medical Sciences
(13)
Medical Sciences
(13)
Melanoma - Drug Therapy
(9)
Pharmacology. Drug Treatments
(9)
Dose-Response Relationship, Drug
(7)
Skin Neoplasms - Drug Therapy
(7)
Antineoplastic Agents
(6)
Interferon-Alpha - Therapeutic Use
(6)
Carcinoma, Renal Cell - Drug Therapy
(5)
Depression
(5)
Drug Administration Schedule
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands

Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon‐α: Course and relationship with psychiatric status

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience

Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands

Pimasertib‐associated ophthalmological adverse events

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry

Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)

IL-12: a promising adjuvant for cancer vaccination

Repeated Administrations of Interleukin (IL)-12 Are Associated with Persistently Elevated Plasma Levels of IL-10 and Declining IFN-γ, Tumor Necrosis Factor-α, IL-6, and IL-8 Responses

Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-α therapy

Phase I Study of Subcutaneously Administered Recombinant Human Interleukin 12 in Patients with Advanced Renal Cell Cancer

Interferon-α Influences Tryptophan Metabolism without Inducing Psychiatric Side Effects

Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant

Pegylated interferon-α2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations

Interleukin 12 induces activation of fibrinolysis and coagulation in humans

Side effects of interferon-alpha therapy

Adverse Effect on Bone Marrow Protection of Prechemotherapy Granulocyte Colony-Stimulating Factor Support

The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon α and lymphokine-activated killer cells

Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response

Neuropsychiatric side effects of interferon-alfa therapy

Abstract 4603: Targeted treatment of metastatic melanoma through interference with Pin1-FOXM1 signaling

Aktive Filter

Suchergebnisse filtern